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INTRODUCTION
Preeclampsia is described as a pregnancy-specific
syndrome that contributes greatly to maternal and fe-
tal morbidity and mortality. Preeclampsia complicates
4 to 8 percent of all pregnancies, and together they
form one member of the deadly triad, along with he-
morrhage and infection. Eclampsia is seizures that
cannot be attributed to other causes in a woman with
preeclampsia.1
Until 2010 preeclampsia was still a leading cause
of maternal mortality, preterm birth, and consequent
neonatal morbidity and mortality. In developing coun-
tries, where access to safe, emergent delivery is less
readily available, preeclampsia claims the lives of
more than 60,000 mothers every year.2
According to WHO, hypertension in pregnancy
contributes 12% of all maternal deaths in the world.
Prevalence of hypertension in pregnancy varies all
Abstract
Objective: To analyze correlation between total antioxidant ca-
pacity measured by Ferric Reducing Ability of Plasma (FRAP) as-
say with severity of preeclampsia.
Method: The cross sectional method was used in this study to
compare TAC of four different groups of study, consists of normal
pregnancy, mild preeclampsia, severe preeclampsia and eclampsia.
The study consisted of 15 women in each group. All of the subjects
met the inclusion criteria and were admitted to Dr. Hasan Sadikin
Hospital and it’s district hospital. The study was conducted from
August until September 2011. 3 ml blood samples were taken and
were measured by FRAP assay in the laboratory PRODIA Jakarta.
Result: There was no significant difference (p<0.05) on sub-
ject’s characteristics based on number of parity and gestational age
among the groups of study. The comparison of TAC measured by
FRAP assay based on ANOVA was significant difference (p<0.01).
The highest mean FRAP assay result appeared in eclampsia which
was 1441.1±315.8, while in severe preeclampsia 1118.8±118.3,
mild preeclampsia 902.4±102.5 and in normal pregnancy 769.3±
117.1. There was significant (p<0.05) positive correlation (ratio
0.880) between TAC measured by FRAP assay with severity of
preeclampsia. Based on prevalence ratio with CI 95% subjects with
FRAP level ≥ 769.3 had about 2.17 times higher risk to develop
mild preeclampsia and subjects with FRAP level ≥ 769.3 had about
2.5 times higher risk to develop severe preeclampsia or eclampsia.
Conclusion: There was a very strong positive correlation
between TAC measured by FRAP assay with the severity of pre-
eclampsia.
[Indones J Obstet Gynecol 2011; 35-4: 155-60]
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Abstrak
Tujuan: Untuk menganalisis hubungan antara kapasitas antiok-
sidan total yang diukur dengan metode FRAP dengan derajat berat-
nya penyakit preeklampsia.
Metode: Penelitian dilakukan secara potong silang dengan
membandingkan KAT dengan metode FRAP pada empat kelompok
penelitian yaitu kehamilan normal, preeklampsia ringan, preeklamp-
sia berat serta eklampsia. Setiap kelompok berjumlah 15 orang
yang memenuhi kriteria inklusi dan datang berobat ke RSUP Dr.
Hasan Sadikin Bandung serta rumah sakit jejaringnya, berlangsung
dari bulan Agustus - September 2011. Sampel darah dipergunakan
sebanyak 3 ml lalu diperiksakan di laboratorium PRODIA Jakarta.
Hasil: Tidak terdapat perbedaan bermakna (p>0,05) pada ka-
rakteristik subjek penelitian dari segi jumlah paritas dan usia ke-
hamilan. Kadar FRAP pada keempat kelompok penelitian berda-
sarkan uji ANOVA menunjukkan perbedaan sangat bermakna
(p<0,01). Kadar FRAP tertinggi ditemukan pada kelompok eklamp-
sia dengan rerata 1441,1±315,8, diikuti preeklampsia berat 1118,8±
118,3, preeklampsia ringan 902,4±102,5 serta kehamilan normal
769,3±117,1. Berdasarkan uji korelasi Rank Spearman terdapat
korelasi positif yang bermakna (p<0,05) dengan rasio sebesar
0,880 antara kadar FRAP dengan derajat berat penyakit preeklamp-
sia. Berdasarkan uji prevalensi rasio dengan CI 95% didapatkan
risiko sebesar 2,17 kali pada kadar FRAP ≥ 769,3 untuk terjadi
preeklampsia ringan serta risiko sebesar 2,5 kali untuk terjadi pre-
eklampsia berat atau eklampsia.
Kesimpulan: Didapatkan korelasi positif dengan kekuatan sa-
ngat kuat antara kadar FRAP dengan derajat berat penyakit pre-
eklampsia.
[Maj Obstet Ginekol Indones 2011; 35-4: 155-60]
Kata kunci: kadar FRAP, kapasitas antioksidan total, preeklampsia-
eklampsia
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over the world about 2.6-7.3%.3 Incidence of pree-
clampsia is affected by multiple factor such as number
of primigravida, socioeconomical status, educational
level, etc. The incidence of preeclampsia in Indonesia
is about 3-10%.4
In Dr. Hasan Sadikin Bandung Hospital in 2002,
the incidence of severe preeclampsia was 7.4% and
in 2010 was 3.19% (192 cases), while incidence of
eclampsia was 1.06% (64 cases).5
The high incidence of preeclampsia and its insig-
nificant decline in the recent decades shows that many
things are still not know about preeclampsia espe-
cially the etiology.
In recent years many efforts have been made in
regard to the individuation of pathophysiological fac-
tors and possible methods of screening women for
preeclampsia before clinical signs and symptoms are
apparent. Preeclampsia likely represents the clinical
end point of multiple contributory factors and it is
unlikely that any single cause will be found. The pri-
mary immunologic, genetic, biochemical, inflamma-
tory basis of preeclampsia still remains speculative.
Although the etiology of preeclampsia remains un-
known it is widely accepted that the disorder are pla-
cental origin and endothelial dysfunction.6-9
The pathogenesis of endothelial dysfunction re-
mains unclear. One of the hypothesis is associated
with oxidative stress, defined as an imbalance bet-
ween free radical damage and antioxidant protec-
tion.6,8-11
Oxidative stress, hyperlipidemia and increased iron
levels in the maternal compartment in preeclampsia
could be responsible for these placental changes by
causing oxidative stress in the placenta.12
Knowledge of the total responses of the serum an-
tioxidant systems in preeclampsia is limited. Radical-
scavenging antioxidants are consumed by the increa-
sed free radical activity associated with this condition
and the total antioxidant capacity (TAC) has been
used to assess free radical activity inderectly. There
are conflicting results concerning this topic. Kharb
found significantly higher total antioxidant capacity
in women with preeclampsia, while Harma found sig-
nificantly lower values in preeclamptic patients.11,13
Because of the difficulty in measuring each anti-
oxidant component of plasma individually and of the
interactions that take place among components, me-
thod that can measure total antioxidant capacity is
used. Many methods that can measure TAC, and there
is still no agreed ’golden standard’ for this examina-
tion.11,14
Benzie and his research group in 1996, for the first
time described a method to measure the total antioxi-
dant capacity known as the ferric reducing ability of
plasma (FRAP). This is a measure of the antioxidant
power, based on the reduction of ferrous ions by the
effect of the reducing power of plasma constituents,
and contributed by low molecular weight antioxidants
of a hydrophilic and hydrophobic character. The low
molecular weight compounds are Vitamin C, Vitamin
E, bilirubin and uric acid. FRAP is said to give more
biologically relevant information than individual an-
tioxidant measurements and which may describe the
dynamic equilibrium between pro-oxidants and anti-
oxidants in the plasma.14,15
 At low pH, when a ferric- tripyridiltriazine (Fe3+-
TPTZ) complex is reduced to the ferrous (Fe2+) form,
an intense blue color with an absorption maximum at
593 nm develops. FRAP is measured total antioxidant
capacity which contributes from 60% uric acid, 15%
ascorbic acid, 10% thiol protein, 5% of tocopherol
and bilirubin.14
Knowledge of the total antioxidant capacity in the
maternal circulation in pregnancy is limited. We chose
to use FRAP because it is cheap, easy and rapid to
perform, requires little plasma volume with direct re-
sult and its equipment is common in biochemical
laboratory. FRAP is regarded as a reliable measure-
ment of over-all ability to resist oxidative damage.11
Also because FRAP assay used method of reduction
of ferric into ferrous ion, this is a distinct advantage
because the levels of Fe were found to increase sig-
nificantly in preeclampsia.12
The FRAP value in the maternal circulation could
be influenced by the concentration of uric acid. The
high contribution of uric acid as an antioxidant that
is measured in FRAP examination is thought to be
one of the drawbacks of this study because of the
presence of increased uric acid in preeclampsia. How-
ever Harsem in her research did not found any posi-
tive correlation between plasma levels of FRAP and
serum concentrations of uric acid in preeclampsia.16
Research on TAC with FRAP method in pree-
clampsia is still rarely done. Throughout our search-
ing, there are two studies that measured TAC with
FRAP assay in preeclampsia having results that sup-
ported each other. Research conducted by Harsem in
Norway in 2006 obtained TAC which was signifi-
cantly higher in preeclampsia than normal pregnan-
cy16, while research conducted in Jakarta by Noroyo-
no Wibowo in 2010 obtained values in preeclampsia
did not significantly higher than normal pregnancy.17
Another study by Zusterzeel in 2001 that measured
TAC with FRAP assay in the placental and decidual
gained levels in preeclampsia which was significantly
lower than in normal pregnancies.18
Researchers are interested in adding justification of
the above research results, by conducting a different
research to analyze the relationship between TAC
measured by FRAP assay in plasma and the severity
of preeclampsia, especially in the most severe de-
grees, eclampsia.
METHODS
The method used in this research was cross sectional
study to compare TAC measured by FRAP assay of
all subjects. Using four different groups consisted of
normal pregnancy, mild preeclampsia, severe pree-
clampsia and eclampsia. The study consisted of 15
women in each group. All of the subjects met the
inclusion criteria and were admitted to Dr. Hasan
Sadikin Hospital Bandung, Cibabat Hospital, Astana
Anyar Maternity Hospital, Majalaya Hospital, and Dr.
Slamet Garut Hospital. The inclusion criteria are ges-
tational age > 20 weeks, singleton pregnant, liver and
renal function in normal limit, no anemia, no sign of
labor, no systemic infection, not having any antioxi-
dant supplement (Vitamin C and E), and no history
of chronic hypertension.
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3 ml blood samples were taken with vacutainer and
EDTA containing vials was used. The total antioxi-
dant capacity by FRAP assay was measured in the
laboratory PRODIA Jakarta. The blood samples were
kept in ice (2-8°C) for maximum 60 minutes until
centrifugation at 2000 G for 10 min at 4°C. The
plasma was obtained and stored on vial containing
0,3 ml plasma. FRAP solution contained 300 mmol/li-
ter acetate buffer, pH 3,6; 10 mmol TPTZ (2,4,6
tripyridyl-s-triazine) in 40 mmol/liter HCl; 20 mmol/
liter FeCl3.6H20. Aqueous solution (H2O) 33 μl was
added to 1000 μL FRAP solution at temperature 37°C
and used for calibration and control. 33 μl sample of
plasma was added to 1000 μl freshly prepared FRAP
reagent and incubated for 4 min at 37°C. Absorbance
against the blank was read at 593 nm compared with
0 min. The antioxidant capacity was calculated using
a calibration curve of known amounts of Fe2+/l. The
final results were converted to millimoles of
Fe2+/l.14,16
All of data were analyzed by SPSS 18.0 for Win-
dows to compare the characteristic of the four subject
groups and to compare the TAC measured by FRAP
assay in each group. To analyze the correlation of
TAC measured by FRAP assay with severity of pre-
eclampsia, Rank Spearman test was used. To calculate
the risk of FRAP assay to cause preeclampsia and
eclampsia, prevalence ratios with 95% of confidence
intervals were used.
RESULT
The study was conducted from August to September
2011 and obtained 60 subjects that met the inclusion
criteria, 15 subjects for each group.
Subject’s characteristic based on number of parity
and gestational age among the groups of study were
comparable and not significantly different (p<0.05).
The mean gestational age from normal pregnancy
group was 34.5, mild preeclampsia was 37.3, severe
preeclampsia was 38.0 and eclampsia was 35.4. Thus,
the four groups of subjects were homogeneous so the
proper studies can be compared.
Table 1 showed that the highest mean FRAP level
result was found in eclampsia which was 1441.1 ±
315.8, severe preeclampsia was 1118.8 ± 118.3, mild
preeclampsia was 902.4 ± 102.5 and in normal preg-
nancy was 769.3 ± 117.1. Analysis of variance (ANO-
VA) was found to be significantly different (p<0.01)
among each group of study.
In post hoc tests based on Games-Howell test it
was found significant difference (p<0.05) between
FRAP levels in normal pregnancy and in mild pree-
clampsia, whereas among groups of normal preg-
nancy, severe preeclampsia and eclampsia it was
found a very significant difference (p<0.01). In these
test was also found a very significant difference
(p<0.01) between groups with mild preeclampsia and
severe preeclampsia and between mild preeclampsia
and eclampsia, whereas significant differences (p<
0.05) was found between severe preeclampsia and
eclampsia groups.
Based on Rank Spearman correlation test at the in-
terval confidence of 95%, obtained p-value of 0.021
between TAC measured by FRAP assay and severity
of preeclampsia. This indicated that there was a sig-
nificant correlation between TAC measured by FRAP
assay and severity of preeclampsia (p<0.05). Correla-
tion value of 0.880 indicated that there was a very
strong positive correlation based on the criteria
Gamma and Somers’d (Table 2).
Table 2. Correlation between total antioxidant capacity measu-
red by FRAP assay and severity of preeclampsia
Variable correlation rS p
Total antioxidant capacity measured by
FRAP assay and severity of preeclampsia 0.880 0.021*
Note: rS = Rank Spearman correlation coefficient
Table 3 showed that in the normal pregnancy group
there were six subjects (40%) with FRAP levels ≥
769 μmol/liter and 9 subjects (60%) with FRAP levels
<769 μmol/liter, while in the mild preeclampsia group
there were 13 subjects (86.7%) with FRAP levels
≥769 μmol/liter and 2 subjects (13.3%) with FRAP
levels <769 μmol/liter. The analysis showed that
prevalence ratio was 2.17 which meant that subjects
with FRAP level higher than 769 μmol/liter had risk
about 2.17 times to develop mild preeclampsia.
The whole subjects of severe preeclampsia and
eclampsia had FRAP levels ≥ 769 μmol/liter. The
prevalence ratio was 2.50 which meant that subjects
with FRAP level higher than 769 μmol/liter had risk
Tabel 1. Comparison of mean total antioxidant capacity measured by FRAP assay on four groups of study
FRAP level
 (μmol/liter)
Research groups
Statistic testNormal
Pregnancy
(n=15 )
Mild
Preeclampsia
(n=15 )
Severe
Preeclampsia
(n=15 )
Eclampsia
(n=15 )
Mean (±SD) 769.3 (117.1) 902.4 (102.5) 1118.9 (118.3) 1441.1 (315.8) F = 37.412
p < 0.01Range 554 - 1036 712 - 1048 918 - 1286 1078 - 2160
Note: F = F test (analysis of variance)
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about 2.50 times to develop severe preeclampsia or
eclampsia.
DISCUSSION
Characteristics of research subjects
The characteristics of research subjects which were
compared in this study consisted of parity and gesta-
tional age because it had been speculated that parity
and gestational age would be the confounding factor
toward the occurrence of preeclampsia. In order to be
compared in this study, the characteristics of the sub-
jects among the four groups should be homogeneous.
Davidge, et al stated that the plasma antioxidant
activity showed an increase in the second and third
trimester of pregnancy so it had been worried that a
distant range of gestational age would be a confound-
ing factor of the study’s results.19
In this study, the characteristics of the study sub-
jects which were compared consisted of the number
of parity and gestational age. It was feasible for all
four groups to be compared because of the homoge-
neous characteristics of the data obtained.
Zusterzeel in his study, were trying to find the ef-
fect of gestational age on levels of FRAP, testing the
correlation between FRAP levels and gestational age
but the result was there was no correlation between
gestational age and levels of FRAP.18
Correlation between total antioxidant capacity
measured by FRAP assay and severity of pree-
clampsia
This study showed that there was a significant in-
crease of total antioxidant levels measured by the
FRAP assay among the four research groups: normal
pregnancy, mild preeclampsia, severe preeclampsia,
and eclampsia. These results were consistent with the
results of research conducted by Harsem16 and No-
royono17 but contradictory to the results of research
conducted by Zusterzeel.18
The study conducted by Zusterzeel showed that the
total antioxidant levels measured by FRAP assay was
significantly lower in severe preeclampsia than in nor-
mal pregnancy. There were deferrences in material
and specimen used by Zusterzeel in his study. Zus-
terzeel used placental and decidual tissue of pregnan-
cies with severe preeclampsia compared to normal
pregnancy.18
Why did it raise some different results that were
contrary to this study? The reason of this question
could be explained by a study conducted by Serdar
which proved that placental and decidual tissue was
a source of lipid peroxidation that played an important
role in the pathophysiology of preeclampsia. This stu-
dy determined the lipid peroxidation levels by mea-
suring the peroxidation product of complex unsatu-
rated fatty acid membrane that was malonylaldehyde,
which found significantly increased levels of malony-
laldehyde in severe preeclampsia, supported by the
other literature. Increased level of lipid peroxidation
in the placenta and decidua would cause an imbalance
between pro-oxidants and antioxidants in preeclamp-
sia and then caused an endothelial damage as the main
pathogenesis of preeclampsia.10,20
In this study we found that the total antioxidant
capacity measured by FRAP assay was significantly
higher in mild preeclampsia, severe preeclampsia and
eclampsia groups than in normal pregnancy group.
This was consistent with the study conducted by  Har-
sem showed that the total antioxidant capacity mea-
sured by FRAP method was significantly higher in
severe preeclampsia cases than in normal pregnan-
cies.16 These statement were also consistent with the
results obtained by Noroyono in his study which sta-
ted that there was an increase of total antioxidant ca-
pacity measured by FRAP assay in severe preeclamp-
sia group compared to normal pregnancy.17
The existence of increased capacity of total anti-
oxidant in preeclampsia compared to normal preg-
nancy was also confirmed by Kharb in his study even
though he was using the other methods for measuring
the total antioxidant capacity.13 The method that were
used was total radical absorption potentials method
(TRAP), its working principle is different from FRAP
method. FRAP method works based on the reaction
of hydrogen atom transfer (HAT) while the FRAP
method works based on the reaction of single electron
transfer (SET).21
Table 3. Prevalence ratio between mean total antioxidant capacity measured by FRAP assay and severity of preeclampsia
Research groups Mean FRAP Level of Normal Pregnancy (μmol/liter) Prevalence Ratio (95% CI)
≥ 769 < 769
Normal Pregnancy 6 (40%) 9 (60%) 1.0
Mild Preeclampsia 13 (86.7%) 2 (13.3%) 2.17 (1.13-4.15)
Severe Preeclampsia 15 (100%) 0 (0%) 2.50 (1.35-4.65)
Eclampsia 15 (100%) 0 (0%) 2.50 (1.35-4.65)
Note: x2: chi square = 24.378; p<0.01
CI = confidence interval
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Kharb explained that the reason why preeclampsia
led an increase of total antioxidant capacity measured
by TRAP method was due to high levels of uric acid
in serum. The differences in levels of uric acid in
both groups were also found in other studies. Uric
acid contributed as much as 38-47% to the measure-
ment of total antioxidant capacity by TRAP method,
while vitamin C and E respectively contributed as
much as 13-17% and 2-8%. Thiol protein (sulfhydryl
group) actually had the highest plasma concentrations
but it had less effective roles as an antioxidant.13
Similarly, the measurement of total antioxidant ca-
pacity with FRAP method was also markedly influ-
enced by the levels of uric acid. Uric acid antioxidant
contributed as much as 60% to the measurements con-
ducted by the FRAP method, whereas ascorbic acid
contributed as much as 15%, thiol protein 10%, toco-
pherol and bilirubin severally as much as 5%.14,22
However, Harsem found no positive correlation
between plasma levels of FRAP and serum concen-
trations of uric acid in the preeclampsia group. The
FRAP assay has the restriction that it measures
mainly the antioxidant capacity of water-soluble an-
tioxidants (uric acid, Vitamin C, and bilirubin) and to
a lesser extent that of hydrophobic components (Vi-
tamin E) and sulfhydryl groups of proteins.16
It was found that there was an increase of uric acid
levels in preeclampsia and it had been correlated with
increased maternal and fetal morbidity, but this in-
crease was more reflective as a result of an increase
in severity rather than as a cause of preeclampsia it-
self. Uric acid had a protective role as antioxidants
through a mechanism of metal chelation, reacting with
the oxidant (such as hydroxyl radicals and hypo-
chloric acid) to form a more stable product (such as
alantoin), and also through the mechanism of peroxy-
initrite fragmentation.23
The role of uric acid levels in affecting the mea-
surement results of total antioxidant capacity and the
role of bilirubin as antioxidant remain unclear and re-
quire further research.14
The study conducted by Gulmezoglu, et al proved
that an administration of antioxidants (vitamin C, vi-
tamin E, and allopurinol) in patients with severe pree-
clampsia showed a marked improvement of the dis-
ease.24 On the other hand, if the administration of
antioxidant was carried out before the symptoms of
preeclampsia appeared, then this antioxidant supple-
mentation would reduce the incidence of preeclamp-
sia.17,25
This might happen because the antioxidant supple-
mentation after the onset of symptoms of preeclamp-
sia was considered too late, since the beginning of
the preeclamptic process itself had been occured at
the time of trophoblast invasion to desidua.24
CONCLUSIONS
There was significant difference of total antioxidant
capacity measured by FRAP assay among the groups
of study: normal pregnancy, mild preeclampsia, se-
vere preeclampsia, and eclampsia. There is a very
strong positive correlation between total antioxidant
capacity measured by FRAP assay and severity of
preeclampsia with ratio 0.880.
Based on prevalence ratio with CI 95% subjects
with FRAP level ≥ 769,3 had about 2.17 times higher
risk to develop mild preeclampsia and subjects with
FRAP level ≥ 769,3 had about 2.5 times higher risk
to develop severe preeclampsia or eclampsia.
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